AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
AssigneeNeomics Co., Ltd.
InventorsSunghoon Kim, Jin Woo Choi
Life of this patent
Estimating the term…
Abstract
The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer.
Claims12
An isolated siRNA (small interfering RNA) molecule comprising a sense region and an antisense region that down regulates expression of an AIMP2-DX2 gene via RNA interference (RNAi), wherein the sense region comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 27-154, and wherein the antisense region comprises a sequence that is complementary to a nucleotide sequence selected from the group consisting of SEQ ID NOs:
- 27-154, and wherein said siRNA does not down regulate expression of wild type AIMP2 via RNA interference.
A recombinant nucleic acid construct comprising a nucleic acid that is capable of directing transcription of a small interfering RNA (siRNA), the nucleic acid comprising:
- (a) at least one promoter;
- (b) a DNA polynucleotide segment that is operably linked to the promoter, (c) a linker sequence comprising at least 4 nucleotides operably linked to the DNA polynucleotide segment of (b);
- and (d) operably linked to the linker sequence a second polynucleotide, wherein the polynucleotide segment of (b) comprises a polynucleotide that is selected from the group consisting of SEQ ID Nos:
- 27-154, wherein the second polynucleotide of (d) comprises a polynucleotide that is complementary to at least one polynucleotide that is selected from the group consisting of SEQ ID Nos:
- 27-154.
Dependencies are inferred from the claim text.